East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Nitrofurantoin Capsules USP (Monohydrate/Macrocrystals) 100mg. Aurobindo Pharma’s Nitrofurantoin Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Macrobid® Capsules manufactured by Almatica Pharma, LLC. 

Nitrofurantoin Capsules are indicated for:

• The treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus.